Our Team

Our Leadership Team



William Annett

William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., an in vitro diagnostic company successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company focused on diagnosis of the major diseases of pregnancy. Mr. Annett also founded a consumer products company, which became publicly traded on NASDAQ, during his six-year tenure as CEO, and then acquired. At Genentech, Mr. Annett led the Commercial Strategy group, managed large operational projects with several hundred team members, and directed the Project Finance function, which supported all pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he headed the West Coast Life Sciences practice with sales, marketing, and delivery responsibilities. His clients included most of the major biotech and pharmaceutical companies in the western United States. Mr. Annett is a member of the Board of Directors of the California Life Sciences Association. He holds an MBA from the Harvard Business School.




Mitch Levine

Mitch Levine joined OncoCyte as Chief Financial Officer in November 2017. Prior to joining OncoCyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies. In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy. Prior to founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies. He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.




Al Parker joined OncoCyte as Chief Operating Officer in August 2018. Mr. Parker is an accomplished business and legal executive with over 25 years of broad domestic and international life sciences experience, having served in executive leadership roles in leading pharmaceutical, biotech, and healthcare companies. With a background in strategic planning, business development and operations, Mr. Parker’s prior roles include Executive Vice President, General Counsel and Corporate Secretary for Sunovion Pharmaceuticals, Senior Vice President and Global Chief Counsel for Wyeth Pharmaceuticals, and Managing Shareholder at GC Legal Advisors, where he also served in interim chief legal and compliance officer and other operating roles at a number of early stage biotech, pharma, and other healthcare related companies. Committed to strong corporate governance, Mr. Parker has been recognized as a Board Governance Fellow by the National Association of Corporate Directors. Mr. Parker earned his Juris Doctor from the University of Pennsylvania Law School, and his undergraduate degree in Economics from Penn State University.




Lyndal Hesterberg

Lyndal Hesterberg Ph.D., joined OncoCyte as a consultant in 2015 and was named Vice President of Development in February of 2016. Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012 where he was responsible for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.




Lyssa Friedman

Lyssa Friedman joined OncoCyte as a consultant in April 2014 and was named VP of Clinical and Regulatory Affairs in September 2015. Ms. Friedman started her career as a registered nurse specializing in oncology, and has led clinical research operations teams for more than 15 years. Ms. Friedman was a founding team member at Veracyte, where she executed a 49-site, 4000-subject clinical validation study that resulted in the launch of the Afirma® Gene Expression Classifier. She later oversaw clinical utility studies that contributed to positive coverage decision from the Centers for Medicare and Medicaid Services and major U.S private insurers. Ms. Friedman is an author of about a dozen peer-reviewed publications and is a frequent speaker on diagnostic development, clinical and regulatory affairs, and reimbursement. Ms. Friedman received her Masters in Public Administration from the University of San Francisco.




William Haack joined OncoCyte as Vice President of Market Access and Business Operations in June 2016. Mr. Haack has 20 years of life sciences experience, having leadership roles at Genentech, Genomic Health & Invitae. Mr. Haack had the great privilege of working on the teams at Genentech that launched Herceptin® and Rituxan® and was also involved in some of the early strategic work at Genentech in the area of molecular diagnostics. At Genomic Health, Mr. Haack lead both US and European Commercial Operations and Market Access teams during his 9 year tenure where he developed the department from infancy to over 120 people and nearly $300 million in annual global revenues. Mr. Haack also served as Adjunct Assistant Professor of Economics at Golden Gate University for 11 years where he taught micro and macro-economic theory. Mr. Haack received an MA in Economics at California State University, Hayward where he specialized in Econometrics.




Kristine Mechem

Kristine C. Mechem joined OncoCyte Corporation as Vice President of Marketing & Planning in August 2015. Dr. Mechem’s leadership and industry experience includes marketing, long range planning,  commercial opportunity assessments and analytic roles spanning from smaller early stage diagnostic companies such as Corra Life Sciences, to larger biopharma companies like Abbott and Genentech.

At Corra Life Sciences, a prenatal diagnostics company, she was a co-founder and in her business development and marketing role worked to secure co-development partners and to license IP from three prominent universities.  At Genentech, Dr. Mechem led the portfolio management and business planning process for a $400M product. Most recently, as a Director of Business Insights and Analytics at Abbott Diabetes Care, she led a team managing the business planning process and tracking key product performance. Dr. Mechem holds a Ph.D. from the University of Chicago, and completed the Stanford Business School Executive Program in Strategy and Organization.

Our Medical Advisory Committee


Thomas Bauer

Dr. Bauer graduated from Jefferson Medical College and pursued his training in general surgery, research and cardiothoracic surgery at Thomas Jefferson university Hospital.  He served as the Chief of Thoracic Surgery at the Helen F Graham Cancer Center at Christiana Care Health System.  He currently serves at the Chief of Thoracic Surgery at Jersey Shore University Hospital and is the Medical Director of Thoracic Oncology at Meridian Health in the Hackensack Meridian Health System.

Dr. Bauer has lead numerous clinical trials and has partnered with industry through device and pharmaceutical investigative trials for many years.  He has authored over 100 manuscripts, chapter, abstracts and presentations related to thoracic surgery.  He has a special interest in lung cancer screening research and clinical trials.  His clinical expertise is in robotic minimally invasive thoracic surgery for the treatment of lung cancer, first rib resections, esophageal cancer, benign foregut surgery and diaphragmatic pacing and reconstruction.




Dr. Hogarth is Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago. He is the Director of Bronchoscopy and is heavily involved in the field of interventional bronchoscopy with numerous publications.

Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine in Cleveland, Ohio. He then completed a residency in Internal Medicine and a fellowship in Pulmonary and Critical Care at The University of Chicago. He has been published in the New England Journal of Medicine, Chest, and many other journals. He serves on the editorial board of CHEST, where he is the section editor for the podcast section.



Edward F. Patz

Dr. Patz is the James and Alice Chen Professor of Radiology and a Professor in Pharmacology and Cancer Biology at Duke University Medical Center. He began his training in High Energy Physics at Harvard University, received his MD from the University of Maryland, completed his residency and thoracic imaging fellowship at the Brigham and Women’s Hospital and Harvard Medical School, and then was appointed to the faculty in the Department of Radiology at the Brigham, Harvard Medical School, and the Dana Farber Cancer Institute. In 1991, he was recruited to the Thoracic Imaging section in the Department of Radiology at Duke.

Dr. Patz is a clinician–scientist, with projects that focus on early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. He has participated in numerous clinical trials including the National Lung Screening Trial (NLST), and for over 20 years has been the principal investigator of a basic science laboratory exploring lung cancer biology.



Anil Vachani

Dr. Vachani received his medical degree from the University of California, San Francisco in 1996, after which he completed internal medicine and pulmonary/critical care training at the University of Pennsylvania. He also holds a Masters in Clinical Epidemiology from the University of Pennsylvania. He is currently an Associate Professor of Medicine in the Pulmonary and Critical Care Division at the University of Pennsylvania in Philadelphia, PA, where he serves as Director of the Lung Nodule Program, Co-Director of the Lung Cancer Screening Program, and Director of Bronchoscopy at the Philadelphia VA Medical Center. He serves on various committees for the American Thoracic Society and is the Vice-Chair of the Thoracic Oncology Network of the American College of Chest Physicians.

Dr. Vachani’s research is focused on the discovery and validation of early detection and treatment prediction biomarkers for lung cancer and mesothelioma. Additional areas of research include studies on the measurement of biomarkers from circulating tumor cells and circulating free DNA, Finally, he is conducting studies on population level uptake of genomic and genetic technologies for treatment decisions in lung cancer using cancer registry and claims data.

Our Board of Directors


Chairman of the Board

Cavan Redmond joined the Board of Directors in September of 2015.  Mr. Redmond is a seasoned healthcare strategist, who has held a number of global leadership positions.  He currently is a partner at Zarsy, LLC.  His global leadership roles include: CEO of WebMD Health Corp., where he oversaw cost rationalizations and streamlined operations to position the company for growth; Senior Vice President and Group President, Pfizer Diversified Businesses.  The Diversified Business included Animal Health, Consumer Healthcare, Capsugel and Nutrition. While at Pfizer he also became the head of Corporate Strategy. While at Wyeth he was the first EVP and General Manager Wyeth Biopharma and President of Wyeth Consumer Healthcare.  He is currently a member of  the Board of Directors for the Arthritis Foundation, where he has served since 2014.   Mr. Redmond holds a MAS degree from Johns Hopkins University and a  BA from the University of Maryland at College Park. He was a 2012 recipient of The Johns Hopkins University Distinguished Alumnus Award.



William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., which created innovative products in the in vitro diagnostics field and was successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company, which worked with a consortium of universities to develop blood tests for the major diseases of pregnancy. Early in his career, Mr. Annett also founded a consumer products company, which he led for six years as CEO. During his tenure, the company became publicly traded on NASDAQ and was then acquired.

At Genentech, Mr. Annett led the Commercial Strategy group and managed large operational projects with several hundred team members. He also directed the Project Finance function for R&D, which supported all development pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he founded, built, and headed Accenture’s West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory. His clients included most of the major biotech and pharmaceutical companies in the western United States.

Mr. Annett holds an MBA from the Harvard Business School.


Mr. Andrews is the Founder and Principal of The Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding The Bethesda Group, he served as President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division. Previously, Mr. Andrews served as Chief Executive Officer and Segment Leader of GE Molecular Diagnostics at Clarient Inc. from 2004 until 2012 and oversaw the transition into GE Healthcare and expansion of GE’s presence in oncology. While at Clarient, he transformed ChromaVision Medical Systems from a device manufacturer to a comprehensive cancer diagnostics company. Mr. Andrews currently serves on the Board of Directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.


Andy Arno was appointed as a member of the Board of Directors in June 2015. He is currently Vice Chairman of “The Special Equities Group” at Chardan Capital Markets, LLC, a privately held investment banking firm. He was previously Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., as well as President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He also served as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of its parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the Boards of Asterias Biotherapeutics, Comhear, and Smith Micro Software, Inc. He is a graduate of George Washington University.


Alfred D. Kingsley joined the Board of Directors in 2009 and was previously Chairman of the Board. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt Corp. served as our financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.


Andrew J. Last joined the Board of Directors in December 2015. In January of 2018, Dr. Last was appointed as Chief Commercial Officer at Berkeley Lights. Previously, he served as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016, Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004, Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marking 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph. D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.


Adi Mohanty joined the Board of Directors in April 2015. Mr. Mohanty currently has served as BioTime’s, Chief Operating Officer since December 2014 and Co-Chief Executive Officer since October 2015. He was formerly with Shire plc, a biotechnology company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as Vice President at Transkaryotic Therapies from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty received an MBA degree from Saint Mary’s College and has an MS and BS in Chemical Engineering.